The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).
 
Mark Christopher Markowski
Honoraria - Clovis Oncology; Exelixis
 
Mary-Ellen Taplin
Honoraria - Abbvie; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Constellation Pharmaceuticals; GlaxoSmithKline; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Myovant Sciences; Pfizer; Pfizer; Progenics; Research to Practice; Roivant; UpToDate
Consulting or Advisory Role - Arcus Ventures (I); AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Hao Wang
No Relationships to Disclose
 
Aliya Lalji
No Relationships to Disclose
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
 
Catherine Handy Marshall
Consulting or Advisory Role - Bayer; Dendreon; McGraw-Hill Education
Research Funding - Conquer Cancer Foundation/Bristol-Myyers Squibb
Travel, Accommodations, Expenses - Bayer; Dava Oncology
 
Michael Anthony Carducci
Consulting or Advisory Role - Exelixis; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); pfizer (Inst)
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Seagen
Travel, Accommodations, Expenses - Veru
 
Angelo M De Marzo
Consulting or Advisory Role - Cepheid
Research Funding - Janssen Research & Development
 
Samuel R. Denmeade
Stock and Other Ownership Interests - Sophiris Bio
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Sophiris Bio
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Lilly; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi